European Association of Neuro-Oncology (EANO)



EANO is the pan-European organisation that represents all the clinical and scientific disciplines involved in the diagnosis and treatment of brain and central nervous system malignancies and of the effects of cancer, or its treatment, on the nervous system. EANO exists to stimulate interaction and collaboration between those with an interest in Neuro-oncology and provides educational activities through biennial EANO congresses and other conferences and via the EANO website. At a European level it works with ECCO

to advocate best practice in Europe and the importance of research funding.

Today EANO has over 600 members from more than 30 countries, in Europe and across the world. EANO cooperates with national Neuro-oncology societies and allied groups to stimulate international cooperation in research and clinical training. EANO has organised 8 biennial EANO scientific congresses (Maastricht 1994, Würzburg 1996, Versailles 1998, Copenhagen 2000, Florence 2002, Vienna 2006 and Barcelona 2008) and the joint EANO/World Federation for Neuro-oncology conference, which was held in Edinburgh in May 2005.

A special educational program is planned for young researchers from Central and Eastern Europe with the goal of promoting a high standard Neuro-oncological qualification and favouring a more intense integration with these countries. In 2009 and 2010 EANO members can apply for fellowships. More information will be published soon on the EANO website.

If you have an interest in Neuro-oncology, we would be delighted to see you at the next EANO meeting, scheduled September 16–19, 2010, Maastricht, the Netherlands.

We are looking for active members – please register as a member via our website.

For further information contact:

E-mail: office@eano.eu

www.eano.eu

European Association of Urology (EAU)

Leading science into the future

The European Association of Urology (EAU) is a prominent organisation that makes its goal to provide consistent support to urology experts from all over the world and to represent its members in a competent and efficient manner. All professionals who are active in the field of urology, including urology nurses, are welcome to join the growing ranks of EAU members.

The EAU was established in 1972, prompted by developments in the emerging European community. It came to life through the efforts of several distinguished European urologists and the enthusiasm of Prof. G. Ravasini. The EAU's first congress was held in Padua, Italy two years later. At the same time the official journal of the EAU, *European Urology* (current IF 5.634), was established. Under the leadership of Prof. F. Debruyne, the European Association of Urology underwent a number of structural changes in the 1990s, enabling it to become the modern organisation that it is today. Prof. Per-Anders Abrahamsson is the current Secretary General of the EAU.

Currently the EAU is a leading urological association, which actively promotes intensification of research and practice in the numerous subspecialties of this field ranging from andrology and uro-oncology to uro-technology. Each year, the EAU organises various section meetings that offer the newest updates in the relevant subspecialty, at the same time providing a very sound platform for expert exchange of ideas.

The European Association of Urology understands the growing need for interdisciplinary collaboration. A number of EAU's on-going projects cover this important objective, such as the European Multidisciplinary Meeting on Urological Cancers (EMUC), an event organised in association with ESMO and ESTRO.

The EAU organises highly esteemed conferences and courses in the field of urology, with the Annual EAU Congress topping the list. This congress is one of the largest urology events in the world and attracts thousands of experts to its venues each year. Various regional meetings and courses enable the EAU to reach out to smaller groups of local professionals meeting their need for education and exchange of knowledge.

For further information, contact:

E-mail: EAU@uroweb.org

www.uroweb.org

European Organisation for Research and Treatment of Cancer (EORTC)



The European Organisation for Research and Treatment of Cancer (EORTC) is an international association under Belgian law created in 1962.

The aims of the EORTC are to develop, conduct, coordinate, and stimulate translational and clinical cancer research in Europe to improve the management of cancer and related problems by increasing both survival and patient quality of life. The ultimate goal of the EORTC is to establish state-of-the-art cancer treatment to improve survival rate, quality of life and quality of care for all patients with cancer.

The EORTC is primarily devoted to high-quality clinical research to establish optimal therapeutic strategies via large multi-center clinical studies in a multidisciplinary approach leading to state-of-the-art treatment.

In line with the increasingly important role of functional imaging in trials involving translational research and having endpoints linked to biological markers, the EORTC Board has decided to establish an Imaging Group to drive the development of treatment strategies tailored to the biological characteristics of a particular tumour.

EORTC Headquarters has instituted quality assurance in radiotherapy (QART), and these measures have resulted in measurably significant improvement in treatment delivery and patient outcome in radiotherapy. The EORTC has initiated a European tumor bank project to improve and harmonise the histological review and to promote translational research in EORTC trials.

The EORTC Headquarters' Early Project Optimisation Department (EPOD) lends support and methodological expertise to the EORTC groups for all new projects.

A Network of Core Institutions (NOCI) has been formed as part of the overall EORTC strategy. NOCI is based on core recruiting academic centres across Europe, specifically apt to develop projects with important translational research components.

EORTC Headquarters comprises about 160 staff members (15 nationalities) including medical doctors, statisticians, PhD's quality of life specialists, scientific and administrative staff, computer specialists, and research fellows.

ECCO – the European CanCer Organisation Full Members

All EORTC research projects and clinical studies are peer reviewed and have to be approved by the relevant EORTC Committees.

An Academic Research Fund has been created to allocate support for clinical trials of excellence submitted to the Board.

Over 6000 new patients are treated each year according to EORTC protocols.

For further information please visit: www.eortc.be

European Society of Gynaecological Oncology (ESGO)



The Voice of Gynaecological Oncology in Europe

ESGO is a forum for professionals dedicated to the care of women affected by gynaecological cancer and a principal authority concerned with Gynaecological Oncology in Europe.

Our objective is to promote communication with scientific and professional bodies in order to create a dynamic and democratic European platform of individual professionals including specialists, fellows and nurses for networking, sharing of knowledge and improving gynaecological cancer care in Europe.

ESGO achieves its aims through ESGO biennial meetings, ESGO's official journal, the International Journal of Gynaecological Cancer (IJGC), the organisation of educational events, workshops and backed meetings (endorsed or supported meetings). We are also involved in hospital accreditation and setting up accredited training programs, Travelling Fellowships and other activities.

In order to fulfil our objectives we need the involvement of all those who care about gynaecology to join us and support our effort.

NEW! Discover our 3 new features offered to ESGO members:

E-SERIES 2009 – Exclusive presentations given by internationally renowned speakers, brought directly to your home or office.

ESGO Forum – Online video library and access to a wide online community.

ENYGO – Junior activities at the Biennial Congress.

For further information contact:

ESGO Administrative Office c/o Kenes International 1-3 rue Chantepoulet P.O. Box 1726

CH-1211 Geneva 1, Switzerland

Tel: +41 22 906 91 50 Fax: +41 22 732 28 50 E-mail: info@esgo.org

www.esgo.org

European School of Oncology (ESO)



The European School of Oncology (ESO) was founded by Umberto Veronesi and Laudomia Del Drago in 1982, with the aim of contributing to the reduction of deaths from cancer due to late diagnosis and/or inadequate treatment. ESO's mission is reflected in its motto 'Learning to Care', which stresses the concept of studying and learning and also of caring for the patient in a global sense. By improving the skills of all health professionals dealing with cancer patients, ESO shortens the length of time needed

to transfer knowledge from research centres to daily practice, combining advanced technology with humanism in care.

'Learning to Care' is the motto of the School. The European School of Oncology has always given great importance to the learning process. Since its attention is focused on the clinical aspects of the cancer problem, care is the ultimate goal of its commitment to improve the oncological skills of health professionals. Care and not only treatment is of paramount importance to us because ESO believes in the holistic approach to the cancer patient.

ESO organises a wide range of courses, covering many different topics and relevant to all health professionals in oncology, regardless of experience. ESO's events are clinically-oriented and involve research conducted with human subjects with whom the speaker has interacted directly. ESO's courses are organ-oriented but the disease is approached from all possible sides, from epidemiology to surgery, from basic science to rehabilitation. The involvement of interdisciplinary methods and approaches is a key aspect. ESO believes that cancer is a biological problem but also a human, social and psychological issue. Medical doctors play a crucial role in the fight against cancer, but nurses, psychologists, social workers and technicians of the various disciplines do too. ESO values the enormous role that patients play in the treatment and cure of cancer and since its inception has been open to advocacy.

For further information contact:

European School of Oncology Via del Bollo, 4 20123 Milan, Italy

Tel: +39 02 8546 451 Fax: +39 02 8546 4545 E-mail: eso@eso.net

www.eso.net

European Society of Oncology Pharmacy (ESOP)



Our capability needs a goal – patients need our competence

For all health care practitioners, whatever their profession, the patient is the focus of attention. The causes that induce a need for therapy have to be diagnosed individually and treated in line with generally recognised methods.

International studies and national surveys alike indicate that between 6-13% of hospital admissions relate to conditions whose causes can be attributed to the inappropriate prescription or administration of medication.

The active support of the pharmacist is needed.

ECCO – the European CanCer Organisation - Full Members

The situation regarding oncology patient care differs from each country in Europe. The countries with the most contrary conditions are Belgium and Germany. In particular it is important to consider Oncology pharmacy from the hospital and the ambulatory perspectives.

To be able to ultimately serve all patients in future under the same good conditions the following three main requirements must be fulfilled:

- Standardisation
- Specialisation
- · Accreditation

The European Society of Oncology Pharmacy (ESOP) is a Full Member of ECCO – the European CanCer Organisation which through its member societies, represents the interests of over 50,000 professionals in oncology.

The key objectives of the European Society of Oncology Pharmacy (ESOP) are:

- To promote clinical practice, research and development in drug use and administration for the treatment of cancer patients.
- To make research results available to the public through publications, lectures and seminars
- To encourage the publication of developments in clinical practice through professional activities

The chance of surviving cancer is increasing all the time. The methods of treatment are changing from intermittent IV to continuous oral regimens. Pharmacists must be involved in the safe and effective use of orally administered targeted treatments for cancer which also has to be learned by pharmacists.

As early as possible Oncology Pharmacists need to understand their leading role in organising the best support for patients. They will then be rightfully considered as a supporting pillar in the hall of multi-professionalism.

We are honoured to present our work at this joint ECCO $15 - 34^{th}$ ESMO Multidisciplinary Congress.

Klaus Meier, Germany (President ESOP)

For further information contact:

E-mail: membershipservice@esop.eu

www.esop.eu

European Society of Breast Cancer Specialists (EUSOMA)



The European Society of Breast Cancer Specialists (EUSOMA) is a multidisciplinary society committed to increase contacts among specialists in Breast Cancer, improve and harmonise the quality of patient care in Europe, encourage the multidisciplinary approach and the establishment of Breast Units, foster a voluntary certification process.

The main society activities are the publication of consensus statements on new controversial aspects in breast cancer care and the promotion of training and qualification of breast cancer specialists through training programmes for young MDs.

For further information contact:

EUSOMA Via del Pratellino, 7 50131 Firenze, Italy

E-mail: secretariat@eusoma.org

www.eusoma.org